GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Forward Dividend Yield %

PLx Pharma Winddown (PLx Pharma Winddown) Forward Dividend Yield % : 0.00% (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Forward Dividend Yield %?

As of today (2024-04-29), the Forward Annual Dividend Yield of PLx Pharma Winddown is 0.00%.

As of today (2024-04-29), the Trailing Annual Dividend Yield of PLx Pharma Winddown is 0.00%.

PLXPQ's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.89
* Ranked among companies with meaningful Forward Dividend Yield % only.

PLx Pharma Winddown's Dividends per Share for the three months ended in Sep. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of PLx Pharma Winddown's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma Winddown's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where PLx Pharma Winddown's Forward Dividend Yield % falls into.



PLx Pharma Winddown Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


PLx Pharma Winddown  (OTCPK:PLXPQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


PLx Pharma Winddown Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Executives
Rita M O'connor officer: Chief Financial Officer 4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano director, officer: Chief Executive Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino director, officer: Executive Chairman 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden director 1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh director C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman officer: Chief Operating Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden officer: Acting Chief Financial Officer 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381

PLx Pharma Winddown (PLx Pharma Winddown) Headlines